Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and… (NCT07187479) | Clinical Trial Compass
RecruitingNot Applicable
Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus
United States120 participantsStarted 2025-10-14
Plain-language summary
The purpose of this research is to evaluate outcomes of physiologic insulin re-sensitization (PIR) in patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM).
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Is age 18 or older (male or female)
* Have a documented diagnosis of CKD stage 3b, 4, or 5 and T2DM of 6 months or greater prior to screening. Patients may have treatment regimens associated with T2DM that include diabetic oral and/or injectable medications including insulin and/or GLP-1 receptor agonists.
* In the opinion of the Investigator, has been on an appropriate, stable regimen for management of any complications present for the past six (6) months.
* In the opinion of the Investigator, is able to do all of the following:
* Provide valid informed consent.
* Understand and comply with study procedures as presented in the consent process.
* Has the capacity or support to attend all required visits.
* If female, the subject must meet either of the following sets of conditions:
o Is of non-childbearing potential, defined as meeting either of the following criteria:
* Age ≥50 years and post-menopausal for at least one (1) year
* Surgically sterile due to bilateral tubal ligation, bilateral oophorectomy, or hysterectomy
* Is of childbearing potential and meets both of the following criteria:
* Has a negative serum pregnancy test (beta-human chorionic gonadotropin) at screening.
* Agrees to practice an acceptable method of birth control (contraception) from screening until at least 30 days after last study treatment
Exclusion Criteria:
* Has in the past two (2) years received treatment for a malignancy.
* Current pregnancy or intends t…